Indo US Bio-Tech Ltd
Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds[1]
- Market Cap ₹ 230 Cr.
- Current Price ₹ 115
- High / Low ₹ 250 / 110
- Stock P/E 45.5
- Book Value ₹ 21.0
- Dividend Yield 0.22 %
- ROCE 15.4 %
- ROE 16.9 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 191 to 152 days.
Cons
- Tax rate seems low
- Company has high debtors of 152 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| 39.76 | 39.39 | 49.39 | |
| 35.78 | 34.04 | 42.60 | |
| Operating Profit | 3.98 | 5.35 | 6.79 |
| OPM % | 10.01% | 13.58% | 13.75% |
| -0.01 | 0.03 | 0.18 | |
| Interest | 0.88 | 1.18 | 1.20 |
| Depreciation | 0.23 | 0.27 | 0.46 |
| Profit before tax | 2.86 | 3.93 | 5.31 |
| Tax % | 11.54% | -24.68% | 4.71% |
| 2.53 | 4.90 | 5.06 | |
| EPS in Rs | 1.74 | 3.38 | 2.77 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 47% |
| 3 Years: | 8% |
| 1 Year: | -52% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| Equity Capital | 6.07 | 6.07 | 9.17 |
| Reserves | 10.37 | 15.27 | 29.34 |
| 8.58 | 11.57 | 12.84 | |
| 9.68 | 10.80 | 4.27 | |
| Total Liabilities | 34.70 | 43.71 | 55.62 |
| 1.41 | 2.37 | 5.55 | |
| CWIP | 1.28 | 1.99 | 2.32 |
| Investments | 0.00 | 0.00 | 0.00 |
| 32.01 | 39.35 | 47.75 | |
| Total Assets | 34.70 | 43.71 | 55.62 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| -0.84 | 0.16 | 2.70 | |
| -0.57 | -1.78 | -5.44 | |
| 1.53 | 1.55 | 2.65 | |
| Net Cash Flow | 0.12 | -0.07 | -0.09 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|
| Debtor Days | 192.60 | 228.97 | 151.87 |
| Inventory Days | 750.51 | ||
| Days Payable | 666.84 | ||
| Cash Conversion Cycle | 276.26 | 228.97 | 151.87 |
| Working Capital Days | 137.43 | 184.58 | 255.03 |
| ROCE % | 17.68% | 15.45% |
Documents
Announcements
-
Board Meeting Intimation for Consider, Approve And Take On Record The Un-Audited Financial Results Of The Company Along With The Limited Review Reports For The Quarter And Nine Months Ended December 31, 2025;
12 Jan - Board meeting on 21 Jan 2026 to approve Q3/9M unaudited results for Dec 31, 2025; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jan - Certificate under Reg 74(5) of SEBI DP Reg. for the quarter ended on 31st Dec 2025.
-
Closure of Trading Window
31 Dec - Trading window closed from Jan 1, 2026 until 48 hours after unaudited Q4 2025 results announcement.
-
Disclosure under Regulation 30A of LODR
29 Dec - ED (Raipur) PMLA summons dated Nov 20, 2025, for Principal Officer; no formal charges yet.
-
Indo US Biotech Limited Is Proud To Announce Its Participation In The APSA Seed Congress 2025, Taking Place In Mumbai From 17Th To 20Th November 2025.
17 Nov 2025 - Indo US Biotech to exhibit at APSA Seed Congress Mumbai, 17–20 Nov 2025, Booth RB18, Table 13.
Business Overview:[1]
IUBTL is involved in crop Research and Development through breeding, seed production, processing, packing, and marketing of hybrid and open pollinated varieties of agricultural crops